What is troriluzole?

Troriluzole is an investigational drug that is being studied for the treatment of various neurological and psychiatric disorders, including Alzheimer's disease, autism spectrum disorder, and major depressive disorder.

Troriluzole works by modulating glutamate signaling in the brain, which is believed to play a role in the pathophysiology of these disorders. It acts as a glutamate modulator, working to regulate the levels of glutamate in the brain and potentially improve neuronal function and communication.

Clinical trials have shown promising results for troriluzole in treating certain conditions, with some studies indicating improvements in cognitive function, mood, and overall functioning in patients with neurological and psychiatric disorders.

Troriluzole is not yet approved by the FDA for any indication, but it is currently being investigated in ongoing clinical trials. It is considered to have a favorable safety and tolerability profile based on the results of these trials, and further research is being conducted to determine its efficacy and safety in treating various neurological and psychiatric disorders.